Explore

Trendline Trendline
Sarepta, Amylyx, and Neumora Prepare for Key Milestones Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Prepare for Key Milestones Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Prepare for Key Milestones Amidst Q1 Earnings
Trendline Trendline
Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept
Trendline Trendline
Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark

Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark

Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Expansion Plans

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Expansion Plans

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Expansion Plans
Trendline Trendline
ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Trendline Trendline
IDEAYA Biosciences Reports Positive Trial Results and Financial Update for Q1 2026

IDEAYA Biosciences Reports Positive Trial Results and Financial Update for Q1 2026

IDEAYA Biosciences Reports Positive Trial Results and Financial Update for Q1 2026
Trendline Trendline
FDA Rejection Highlights Challenges in Gene Therapy Approvals

FDA Rejection Highlights Challenges in Gene Therapy Approvals

FDA Rejection Highlights Challenges in Gene Therapy Approvals
Trendline Trendline
FDA Reviews Argenx's Proposal to Expand Vyvgart Label for Myasthenia Gravis Patients

FDA Reviews Argenx's Proposal to Expand Vyvgart Label for Myasthenia Gravis Patients

FDA Reviews Argenx's Proposal to Expand Vyvgart Label for Myasthenia Gravis Patients
Trendline Trendline
IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026
Trendline Trendline
Kessler Topaz Meltzer Check, LLP Alerts ImmunityBio Investors of Securities Fraud Class Action

Kessler Topaz Meltzer Check, LLP Alerts ImmunityBio Investors of Securities Fraud Class Action

Kessler Topaz Meltzer Check, LLP Alerts ImmunityBio Investors of Securities Fraud Class Action
Trendline Trendline
Rosen Law Firm Urges Atara Biotherapeutics Investors to Join Securities Class Action Before Deadline

Rosen Law Firm Urges Atara Biotherapeutics Investors to Join Securities Class Action Before Deadline

Rosen Law Firm Urges Atara Biotherapeutics Investors to Join Securities Class Action Before Deadline